Estimated effectiveness of Pfizer-BioNTech vaccine against COVID-19

About The Study: The findings of this case-control study reaffirm current recommendations for broad age-based use of annually updated COVID-19 vaccines given that (1) the BNT162b2 XBB vaccine (Pfizer-BioNTech; 2023-2024 formulation) provided statistically significant additional protection against a range of COVID-19 outcomes and (2) older versions of COVID-19 vaccines offered little, if any, long-term protection, including against hospital admission, regardless of the number or type of prior doses received.  

Corresponding Author: To contact the corresponding author, Sara Y. Tartof, Ph.D., M.P.H., email sara.y.tartof@kp.org.

To access the embargoed study: Visit our For The Media website at this link

(doi:10.1001/jamainternmed.2024.1640)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time